Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2819-2824

  Hugen, N ^a   Verhoeven, R H A ^b   Radema, S A ^a   de Hingh, I H J T ^c   Pruijt, J F M ^d   Nagtegaal, I D ^a   Lemmens, V E P P ^b,e   de Wilt, J H W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b The Netherlands   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant chemotherapy; Colon cancer; Mucinous adenocarcinoma; Prognosis

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; COLORECTAL CARCINOMA; COLORECTAL MUCINOUS ADENOCARCINOMA; DEATH; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONMUCINOUS ADENOCARCINOMA; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT;

ADJUVANT CHEMOTHERAPY; COLON CANCER; MUCINOUS ADENOCARCINOMA; PROGNOSIS;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84887027951     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt378     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Weitz J, Koch M, Debus J et al. Colorectal cancer. Lancet 2005; 365: 153-165.
3. Hamilton SR, Aaltonen LA. Pathology and genetics of tumours of the digestive system. In Hamilton SR, Aaltonen LA (eds), World Health Organization Classification of Tumours, 3rd edition. Lyon, France: IARC 2000; 103-143.
4. Consorti F, Lorenzotti A, Midiri G et al. Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol 2000; 73: 70-74.
5. Kang H, O'Connell JB, Maggard MA et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum 2005; 48: 1161-1168.
6. Hyngstrom JR, Hu CY, Xing Y et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol 2012; 19: 2814-2821.
7. Kanemitsu Y, Kato T, Hirai T et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003; 46: 160-167.
8. Chiang JM, Yeh CY, Changchien CR et al. Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups. Int J Colorectal Dis 2010; 25: 941-947.
9. Melis M, Hernandez J, Siegel EM et al. Gene expression profiling of colorectal mucinous adenocarcinomas. Dis Colon Rectum 2010; 53: 936-943.
10. Catalano V, Loupakis F, Graziano F et al. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol 2012; 23: 135-141.
11. Shin US, Yu CS, Kim JH et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg Oncol 2011; 18: 2232-2239.
12. Nozoe T, Anai H, Nasu S et al. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol 2000; 75: 103-107.
13. Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer 1976; 37: 1891-1900.
14. Mekenkamp LJ, Heesterbeek KJ, Koopman M et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 2012; 48: 501-509.
15. Lin CC, Lin JK, Chang SC et al. Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute. Int J Colorectal Dis 2009; 24: 665-676.
16. Verhulst J, Ferdinande L, Demetter P et al. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol 2012; 65: 381-388.
17. Halvorsen TB, Seim E. Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis. J Clin Pathol 1988; 41: 1068-1072.
18. Wu CS, Tung SY, Chen PC et al. Clinicopathological study of colorectal mucinous carcinoma in taiwan: a multivariate analysis. J Gastroenterol Hepatol 1996; 11: 77-81.
19. Lemmens VE, Klaver YL, Verwaal VJ et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011; 128: 2717-2725.
20. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806.
21. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008; http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005390.pub2/abstract.
22. Oberholzer K, Menig M, Kreft A et al. Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys 2012; 82: 842-848.
23. Catalano V, Loupakis F, Graziano F et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer 2009; 100: 881-887.
24. Negri FV, Wotherspoon A, Cunningham D et al. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 2005; 16: 1305-1310.
25. Maisano R, Azzarello D, Maisano M et al. Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer. J Chemother 2012; 24: 212-216.
26. Compton CC, Fielding LP, Burgart LJ et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994.
27. Sengul N, Wexner SD, Woodhouse S et al. Effects of radiotherapy on different histopathological types of rectal carcinoma. Colorectal Dis 2006; 8: 283-288.
28. Grillo-Ruggieri F, Mantello G, Berardi R et al. Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy. Dis Colon Rectum 2007; 50: 1594-1603.
29. Numata M, Shiozawa M, Watanabe T et al. The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease. World J Surg Oncol 2012; 10: 109.
30. Pande R, Sunga A, Levea C et al. Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum 2008; 51: 50-55.
31. Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
32. Klaver YL, Lemmens VE, Creemers GJ et al. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 2011; 22: 2250-2256.